Lipika R. Pal

The paper identifies transient isoform remodeling as a key mechanism in early MAPKi resistance in melanoma, showing it is distinct from gene expression changes and linked to splicing regulators and developmental pathways.

This study identifies TAZ deficiency as synthetically lethal with BRAF inhibitors in anaplastic thyroid cancer, revealing a mechanism of resistance and a potential therapeutic target.

This paper develops a machine learning framework, EXPRESSO, to predict treatment response from tumor transcriptomics across multiple cancer types and therapies, showing improved performance over existing methods.

This study develops a bispecific antibody targeting MERTK and EGFR to overcome drug resistance in lung cancer with mutations in exons 19, 20, and 21.

This paper introduces TIME_ACT, a transcriptomic signature predicting immune checkpoint blockade response across cancers, validated using histopathology and multiple cohorts.

This study shows that TMPRSS2-ERG fusion promotes resistance to antiandrogens by interacting with GR, suggesting combined GR and AR inhibition could benefit tERG-positive prostate cancer patients.

The paper identifies Mif as a regulator of tumor immune evasion in low intra-tumor heterogeneity melanoma by analyzing single-cell RNA sequencing data and validating in patient data.

The paper predicts anti-SARS-CoV-2 targets by identifying synthetic lethal partners of host genes altered during infection, validated through CRISPR-Cas9 screens and siRNA experiments.

The paper uses genome-scale metabolic modeling to identify SARS-CoV-2-induced metabolic changes and predict antiviral targets validated through drug and genetic screens.

The paper identifies potential causative variants in rare genetic disorders using a gene-centric approach and phenotype-weighted scoring, achieving partial success in matching genomes to clinical profiles.

This paper introduces a formal framework for representing biological mechanisms and applies it to analyze human genetic disease mechanisms.